Description: Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
Home Page: groupedevonian.com
360, rue des Entrepreneurs
Québec,
QC
G5V 4T1
Canada
Phone:
514 248 7509
Officers
| Name | Title |
|---|---|
| Dr. Andre P. Boulet Ph.D. | Chair of the Board, COO & Chief Scientific Officer |
| Mr. Luc D. Gregoire CA, CPA | President, CEO & Director |
| Ms. Colette Laurin C.A., CPA | Interim CFO, Corporate Secretary & Corporate Controller |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.0507 |
| Price-to-Sales TTM: | 1.6522 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 0 |